查詢結果分析
相關文獻
- Fenofibrate Represses Matrix Metalloproteinase-2 in Endothelial Cells
- 鈣離子通道阻斷劑於心血管疾病之臨床應用
- 抗氧化劑與心血管疾病的關係
- Association between Serum Uric Acid and Cardiovascular Risk Factors among Elderly People in Taiwan
- 淺談心血管疾病的基因療法
- 硒與心血管及消化系統疾病之關係
- 臺中市學齡兒童及青少年心血管疾病危險因子之流行病學調查
- 婦女更年期心血管疾病之臨床研究及觀察
- 威而鋼與心血管疾病
- Chemoprevention of Cancer and Cardiovascular Disease by Resveratrol
頁籤選單縮合
題 名 | Fenofibrate Represses Matrix Metalloproteinase-2 in Endothelial Cells=Fenofibrate抑制內皮細胞基質金屬蛋白酶-2 (Matrix Metalloproteinase-2)之表現 |
---|---|
作 者 | 楊家慧; 趙尹慈; 林廷遠; 黃兆康; 沈希哲; 王寧; 陳識中; | 書刊名 | 內科學誌 |
卷 期 | 21:4 2010.08[民99.08] |
頁 次 | 頁270-276 |
分類號 | 418.227 |
關鍵詞 | 心血管疾病; 高酯血症; 酯質代謝; Fenofibrate; MMP-2; Endothelial cell; eNOS; Nitric oxide; |
語 文 | 英文(English) |
中文摘要 | Fenofibrate 已廣泛使用於心血管疾病病患之高酯血症。現今之研究發現,fenofibrate 經由活化過氧化體增生活化接受體α(Peroxisome Proliferator Activated Receptor type alpha, PPARα),改變酯質代謝而達到血管保護作用,而多數証據亦證實fenofibrate經由多效作用 (Pleiotropic effect)對血管造成保護作用。以往研究顯示,血管內皮細胞失調對於動脈硬化之 成因扮演極重要之角色,本實驗探討fenofibrate對於血管內皮細胞保護作用之機轉。血管內 皮細胞經fenofibrate處理後可抑制基質金屬蛋白-2之表現、內皮細胞基質金屬蛋白-2之分 泌與活性。Fenofibrate可經由磷酸化Ser1177造成活化,而經由L-NAME抑制內皮型一氧化氮 合成(eNOS)可減緩fenofibrate造成抑制基質金屬蛋白-2之表現。本實驗證實了fenofibrate 抑制基質金屬蛋白-2需要一氧化氮(NO)之參與。總之,本研究發現fenofibrate可活化eNOS, 增加一氧化氮生物利用度,進而抑制基質金屬蛋白-2之表現。本研究提供fenofibrate造成血 管保護作用之機轉,期望能衍伸為臨床之應用。 |
英文摘要 | Fenofibrate is a widely used to ameliorate hyperlipidemia and/or hypercholesterolemia in patients at risk of cardiovascular disease. To date, most of its favorable effects have been attributed to its activation of peroxisome proliferator activated receptor alpha (PPARα), which alters lipid metabolism, contributing to an improved lipid profile. Lines of evidence suggest pleotrophic effects of fenofibrate in cardiovascular system. Given that endothelium is the frontier of vasculature and its dysfunction is prelude of various vascular disorders, e.g. atherosclerosis and arterial stiffening, we investigated the effect of fenofibrate in human endothelial cell (EC) line (Eahy926). Fenofibrate treatment in ECs repressed matrix metalloproteinase-2 (MMP-2) expression in ECs as well as endothelial MMP-2 secretion, associated with decreased MMP-2 activity. In parallel, fenofibrate activated endothelial nitric oxide synthase (eNOS), demonstrated by Ser1177 phosphorylation. Inhibition of eNOS by L-NAME attenuated fenofibratesuppressed MMP-2, indicating fenofibrate inhibits MMP-2 requires eNOS-derived NO. Collectively, these findings suggest that fenofibrate activates eNOS and increases NO-bioavailability, which in turn suppresses overactivation of MMP-2, contributing to maintenance of endothelial homeostasis. The present study provides a molecular rationale in which fenofibrate exerts vascular protective effects, facilitating the clinical application of its derived medicine. |
本系統中英文摘要資訊取自各篇刊載內容。